This book is based on contributions presented at the 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, which examined recent developments in theranostics – the emerging field of molecular targeting of vectors that can be used for both diagnosis and therapy, when modified accordingly. The focus of this book is on the rapidly developing research into and clinical applications of gallium-68 and other generator-produced PET radionuclides in the personalized diagnosis and treatment of neuroendocrine tumors and other diseases. In addition, new PET radiopharmaceuticals are considered, and the latest ideas and concepts, presented. Theranostics embodies both molecular and personalized medicine. It is at the cutting edge of medicine, and the contents of this volume will be of interest to chemists, physicians, and investigators dealing with generators, PET radiochemistry, molecular imaging, and radionuclide therapy.
Innehållsförteckning
From the contents: Ge-68/Ga-68 generators.- Automation strategies in Ga-68 radiopharmaceutical preparations.- Post-processing via cation exchange cartridges.- Gallium-68 generator integrated system: elution – purification – concentration integration.- Purification and labelling strategies for
68Ga from
68Ge/
68Ga generator eluate.-
67Ga and
68Ga purification studies.- The diversity of [
68Ga]Ga-based imaging agents.- Nanoparticles and phage display selected peptides for imaging and therapy of cancer.- “Click” cyclized gallium-68 labeled peptides for molecular imaging and therapy: Synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.- Early experience with
68Ga-DOTATATE preparation .-
68Ga-radiopharmaceuticals for PET imaging of infection and inflammation.-
68Ga-labeled bombesin analogs for receptor mediated imaging.- A novel
68Ga-labelled pteroic acid-based PET tracer for tumour imaging via the folate receptor.- Measurement of protein synthesis: In vitro comparison of
68Ga-DOTA-puromycin, [
3H]tyrosine and 2-fluoro-[
3H]tyrosine.- Hypoxia imaging agents labeled with positron emitters.- Lu-177/Y-90 intermediate affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.- Divergent role of
68Ga labeled somatostatin analogs in the work-up of patients with NETs.- Differential uptake of
68Ga-DOTATOC and
68Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumours.